BHB810 for Stomach Cancer

This trial tests a new treatment called BHB810 to evaluate its safety and effectiveness for individuals with advanced stomach or gastroesophageal cancer that hasn't responded to other treatments. Participants will receive this treatment through an IV every two weeks. The trial will examine how BHB810 moves through the body and how the body responds. Individuals with advanced stomach or gastroesophageal cancer, who have not had success with existing treatments, might be suitable candidates for this trial. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.

The trial requires that you stop taking certain medications, such as strong CYP3A4 inhibitors or inducers, Pgp inhibitors, or CYP3A4 sensitive substrates, at least 2 weeks before starting the study treatment. Other cancer treatments must also be stopped for a specific period before the trial begins.

A previous study found BHB810 to be safe and effective in significantly reducing tumors. This indicates that patients generally tolerate BHB810 well. Although the study did not specify side effects, the safety results are encouraging. As this study is in the early stages, researchers are closely monitoring for any potential risks. If BHB810 were unsafe, it would not progress in the clinical trial process.¹²³⁴⁵

Most treatments for stomach cancer, like chemotherapy and targeted therapies, work by attacking rapidly dividing cancer cells but can also harm healthy cells. BHB810 is unique because it targets cancer cells more precisely, potentially reducing damage to healthy cells. Researchers are excited about BHB810 because it offers a new mechanism of action that could improve effectiveness and minimize side effects compared to existing treatments. This targeted approach may lead to better outcomes for patients with fewer complications.

Research has shown that treatments targeting HER2, a protein that can promote cancer growth, have potential for treating stomach and gastroesophageal cancers. One study found that 50% of patients with these cancers responded to treatment. Additionally, new combination therapies have greatly improved survival and response rates compared to chemotherapy alone. This trial tests BHB810 at various dose levels to evaluate its effectiveness. Although BHB810 remains under investigation, these findings suggest that targeted therapies might be effective for these cancers.⁶⁷⁸⁹¹⁰